poisar

Stocks · News reference

Canaccord Genuity Maintains Bioventus at Buy, Lowers Price Target to $18

Fiscal.ai

Canaccord Genuity has maintained its 'Buy' rating on Bioventus Inc. while adjusting its 12-month price target from $19 to $18.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — Bioventus Inc. (BVS)

    Filed: 2026-11-02 AccNo: 0001665988-26-000050 Size: 838 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits